메뉴 건너뛰기




Volumn 15, Issue 11, 2016, Pages 1421-1430

Ebola virus vaccines – reality or fiction?

Author keywords

animal model; Ebolavirus; filovirus; prophylaxis; vaccine

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; EBOLA VACCINE; VIRUS VECTOR;

EID: 84991735020     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1080/14760584.2016.1178068     Document Type: Review
Times cited : (26)

References (89)
  • 1
    • 84974717508 scopus 로고    scopus 로고
    • Filoviridae: Marburg and Ebola viruses
    • Knipe D.M., Howley P.M., (eds), Philadelphia (PA): Lippincott Williams & Wilkins
    • H.Feldmann, A.Sanchez, T.W.Geisbert Filoviridae:Marburg and Ebola viruses. In:D.M.Knipe, P.M.Howley, editor. Fields virology. Philadelphia (PA):Lippincott Williams & Wilkins; 2013. p. 923–956.
    • (2013) Fields virology , pp. 923-956
    • Feldmann, H.1    Sanchez, A.2    Geisbert, T.W.3
  • 2
    • 0032566901 scopus 로고    scopus 로고
    • The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer
    • V.A.Volchkova, H.Feldmann, H.D.Klenk, et al. The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer. Virology. 1998;250:408–414.
    • (1998) Virology , vol.250 , pp. 408-414
    • Volchkova, V.A.1    Feldmann, H.2    Klenk, H.D.3
  • 3
    • 79956064784 scopus 로고    scopus 로고
    • A new Ebola virus nonstructural glycoprotein expressed through RNA editing
    • M.Mehedi, D.Falzarano, J.Seebach, et al. A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J Virol. 2011;85:5406–5414.
    • (2011) J Virol , vol.85 , pp. 5406-5414
    • Mehedi, M.1    Falzarano, D.2    Seebach, J.3
  • 4
    • 84991729160 scopus 로고    scopus 로고
    • Ebola virus disease – Democratic Republic of Congo
    • Geneva: WHO
    • WHO. Ebola virus disease – Democratic Republic of Congo. Disease Outbreak News. Geneva:WHO; 2014.
    • (2014) Disease Outbreak News
  • 5
    • 0031688699 scopus 로고    scopus 로고
    • A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever
    • M.Bray, K.Davis, T.Geisbert, et al. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis. 1998;178:651–661.
    • (1998) J Infect Dis , vol.178 , pp. 651-661
    • Bray, M.1    Davis, K.2    Geisbert, T.3
  • 6
    • 0034993883 scopus 로고    scopus 로고
    • The role of the Type I interferon response in the resistance of mice to filovirus infection
    • M.Bray. The role of the Type I interferon response in the resistance of mice to filovirus infection. J Gen Virol. 2001;82:1365–1373.
    • (2001) J Gen Virol , vol.82 , pp. 1365-1373
    • Bray, M.1
  • 7
    • 0032993240 scopus 로고    scopus 로고
    • Pathogenesis of experimental Ebola virus infection in guinea pigs
    • B.M.Connolly, K.E.Steele, K.J.Davis, et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis. 1999;179(Suppl 1):S203–S217.
    • (1999) J Infect Dis , vol.179 , pp. S203-S217
    • Connolly, B.M.1    Steele, K.E.2    Davis, K.J.3
  • 8
    • 84871768273 scopus 로고    scopus 로고
    • A Syrian golden hamster model recapitulating ebola hemorrhagic fever
    • H.Ebihara, M.Zivcec, D.Gardner, et al. A Syrian golden hamster model recapitulating ebola hemorrhagic fever. J Infect Dis. 2013;207:306–318.
    • (2013) J Infect Dis , vol.207 , pp. 306-318
    • Ebihara, H.1    Zivcec, M.2    Gardner, D.3
  • 9
    • 0036094058 scopus 로고    scopus 로고
    • Evaluation in nonhuman primates of vaccines against Ebola virus
    • T.W.Geisbert, P.Pushko, K.Anderson, et al. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis. 2002;8:503–507.
    • (2002) Emerg Infect Dis , vol.8 , pp. 503-507
    • Geisbert, T.W.1    Pushko, P.2    Anderson, K.3
  • 10
    • 0029686711 scopus 로고    scopus 로고
    • Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis
    • E.Ryabchikova, L.Kolesnikova, M.Smolina, et al. Ebola virus infection in guinea pigs:presumable role of granulomatous inflammation in pathogenesis. Arch Virol. 1996;141:909–921.
    • (1996) Arch Virol , vol.141 , pp. 909-921
    • Ryabchikova, E.1    Kolesnikova, L.2    Smolina, M.3
  • 11
    • 67449089968 scopus 로고    scopus 로고
    • Development and characterization of a mouse model for Marburg hemorrhagic fever
    • K.L.Warfield, S.B.Bradfute, J.Wells, et al. Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol. 2009;83:6404–6415.
    • (2009) J Virol , vol.83 , pp. 6404-6415
    • Warfield, K.L.1    Bradfute, S.B.2    Wells, J.3
  • 12
    • 84943268225 scopus 로고    scopus 로고
    • Modeling the disease course of Zaire ebolavirus infection in the Outbred Guinea Pig
    • R.W.Cross, K.A.Fenton, J.B.Geisbert, et al. Modeling the disease course of Zaire ebolavirus infection in the Outbred Guinea Pig. J Infect Dis. 2015;212(Suppl 2):S305–S315.
    • (2015) J Infect Dis , vol.212 , pp. S305-S315
    • Cross, R.W.1    Fenton, K.A.2    Geisbert, J.B.3
  • 13
    • 0032907635 scopus 로고    scopus 로고
    • Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients
    • S.Baize, E.M.Leroy, M.C.Georges-Courbot, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med. 1999;5:423–426.
    • (1999) Nat Med , vol.5 , pp. 423-426
    • Baize, S.1    Leroy, E.M.2    Georges-Courbot, M.C.3
  • 14
    • 0034006617 scopus 로고    scopus 로고
    • Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses
    • T.W.Geisbert, L.E.Hensley, T.R.Gibb, et al. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest. 2000;80:171–186.
    • (2000) Lab Invest , vol.80 , pp. 171-186
    • Geisbert, T.W.1    Hensley, L.E.2    Gibb, T.R.3
  • 15
    • 38449094420 scopus 로고    scopus 로고
    • Lymphocyte death in a mouse model of Ebola virus infection
    • S.B.Bradfute, D.R.Braun, J.D.Shamblin, et al. Lymphocyte death in a mouse model of Ebola virus infection. J Infect Dis. 2007;196(Suppl 2):S296–S304.
    • (2007) J Infect Dis , vol.196 , pp. S296-S304
    • Bradfute, S.B.1    Braun, D.R.2    Shamblin, J.D.3
  • 16
    • 64749097604 scopus 로고    scopus 로고
    • Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule
    • N.J.Sullivan, J.E.Martin, B.S.Graham, et al. Correlates of protective immunity for Ebola vaccines:implications for regulatory approval by the animal rule. Nat Rev Microbiol. 2009;7:393–400.
    • (2009) Nat Rev Microbiol , vol.7 , pp. 393-400
    • Sullivan, N.J.1    Martin, J.E.2    Graham, B.S.3
  • 17
    • 84943270748 scopus 로고    scopus 로고
    • Considerations in the use of nonhuman primate models of Ebola virus and Marburg virus infection
    • T.W.Geisbert, J.E.Strong, H.Feldmann. Considerations in the use of nonhuman primate models of Ebola virus and Marburg virus infection. J Infect Dis. 2015;212(Suppl 2):S91–S97.
    • (2015) J Infect Dis , vol.212 , pp. S91-S97
    • Geisbert, T.W.1    Strong, J.E.2    Feldmann, H.3
  • 18
    • 84951098598 scopus 로고    scopus 로고
    • Ebola virus infections in nonhuman primates are temporally influenced by glycoprotein poly-U editing site populations in the exposure material
    • J.C.Trefry, S.E.Wollen, F.Nasar, et al. Ebola virus infections in nonhuman primates are temporally influenced by glycoprotein poly-U editing site populations in the exposure material. Viruses. 2015;7:6739–6754.
    • (2015) Viruses , vol.7 , pp. 6739-6754
    • Trefry, J.C.1    Wollen, S.E.2    Nasar, F.3
  • 19
    • 84904199045 scopus 로고    scopus 로고
    • Challenges, progress, and opportunities: proceedings of the filovirus medical countermeasures workshop
    • R.Hirschberg, L.A.Ward, N.Kilgore, et al. Challenges, progress, and opportunities:proceedings of the filovirus medical countermeasures workshop. Viruses. 2014;6:2673–2697.
    • (2014) Viruses , vol.6 , pp. 2673-2697
    • Hirschberg, R.1    Ward, L.A.2    Kilgore, N.3
  • 20
    • 38449100363 scopus 로고    scopus 로고
    • Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge
    • K.L.Warfield, D.L.Swenson, G.G.Olinger, et al. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis. 2007;196(Suppl 2):S430–S437.• First study demonstrating efficacy of the VLP vaccine in NHPs.
    • (2007) J Infect Dis , vol.196 , pp. S430-S437
    • Warfield, K.L.1    Swenson, D.L.2    Olinger, G.G.3
  • 21
    • 84925970450 scopus 로고    scopus 로고
    • Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles
    • K.L.Warfield, J.M.Dye, J.B.Wells, et al. Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles. PLoS One. 2015;10:e0118881.
    • (2015) PLoS One , vol.10 , pp. e0118881
    • Warfield, K.L.1    Dye, J.M.2    Wells, J.B.3
  • 22
    • 84928383358 scopus 로고    scopus 로고
    • Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates
    • A.Marzi, P.Halfmann, L.Hill-Batorski, et al. Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates. Science. 2015;348:439–442.• First study showing efficacy of the ZEBOVΔVP30 vaccine in NHPs.
    • (2015) Science , vol.348 , pp. 439-442
    • Marzi, A.1    Halfmann, P.2    Hill-Batorski, L.3
  • 23
    • 84876306476 scopus 로고    scopus 로고
    • Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus
    • A.S.Herbert, A.I.Kuehne, J.F.Barth, et al. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol. 2013;87:4952–4964.
    • (2013) J Virol , vol.87 , pp. 4952-4964
    • Herbert, A.S.1    Kuehne, A.I.2    Barth, J.F.3
  • 24
    • 84944458438 scopus 로고    scopus 로고
    • Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges
    • R.J.Grant-Klein, L.A.Altamura, C.V.Badger, et al. Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges. Hum Vaccin Immunother. 2015;11:1991–2004.
    • (2015) Hum Vaccin Immunother , vol.11 , pp. 1991-2004
    • Grant-Klein, R.J.1    Altamura, L.A.2    Badger, C.V.3
  • 25
    • 0034735774 scopus 로고    scopus 로고
    • Development of a preventive vaccine for Ebola virus infection in primates
    • N.J.Sullivan, A.Sanchez, P.E.Rollin, et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000;408:605–609.• Introduces the first vaccine protective against ZEBOV in NHPs.
    • (2000) Nature , vol.408 , pp. 605-609
    • Sullivan, N.J.1    Sanchez, A.2    Rollin, P.E.3
  • 26
    • 0042739176 scopus 로고    scopus 로고
    • Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates
    • N.J.Sullivan, T.W.Geisbert, J.B.Geisbert, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 2003;424:681–684.
    • (2003) Nature , vol.424 , pp. 681-684
    • Sullivan, N.J.1    Geisbert, T.W.2    Geisbert, J.B.3
  • 27
    • 84907263544 scopus 로고    scopus 로고
    • Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge
    • D.A.Stanley, A.N.Honko, C.Asiedu, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014;20:1126–1129.• First study demonstrating efficacy of the ChAd3 vaccine in NHPs.
    • (2014) Nat Med , vol.20 , pp. 1126-1129
    • Stanley, D.A.1    Honko, A.N.2    Asiedu, C.3
  • 28
    • 84958213109 scopus 로고    scopus 로고
    • Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection
    • A.Marzi, A.A.Murphy, F.Feldmann, et al. Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection. Sci Rep. 2016;6:21674.• First study demonstrating efficacy of the CMV-based vaccine in NHPs.
    • (2016) Sci Rep , vol.6 , pp. 21674
    • Marzi, A.1    Murphy, A.A.2    Feldmann, F.3
  • 29
    • 84938719389 scopus 로고    scopus 로고
    • Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses
    • M.Meyer, T.Garron, N.M.Lubaki, et al. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses. J Clin Invest. 2015;125:3241–3255.• First study demonstrating efficacy of the HPIV3 vaccine in NHPs.
    • (2015) J Clin Invest , vol.125 , pp. 3241-3255
    • Meyer, M.1    Garron, T.2    Lubaki, N.M.3
  • 30
    • 22544441308 scopus 로고    scopus 로고
    • Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
    • S.M.Jones, H.Feldmann, U.Stroher, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005;11:786–790.• First study showing efficacy of the rVSV–ZEBOV vaccine in NHPs.
    • (2005) Nat Med , vol.11 , pp. 786-790
    • Jones, S.M.1    Feldmann, H.2    Stroher, U.3
  • 31
    • 84940172223 scopus 로고    scopus 로고
    • EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain
    • A.Marzi, S.J.Robertson, E.Haddock, et al. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science. 2015;349:739–742.
    • (2015) Science , vol.349 , pp. 739-742
    • Marzi, A.1    Robertson, S.J.2    Haddock, E.3
  • 32
    • 84878520300 scopus 로고    scopus 로고
    • Antibody quality and protection from lethal ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine
    • J.E.Blaney, A.Marzi, M.Willet, et al. Antibody quality and protection from lethal ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog. 2013;9:e1003389.• First study showing efficacy of the RABV vaccine in NHPs.
    • (2013) PLoS Pathog , vol.9 , pp. e1003389
    • Blaney, J.E.1    Marzi, A.2    Willet, M.3
  • 33
    • 0035031534 scopus 로고    scopus 로고
    • Ebola virus VP40-induced particle formation and association with the lipid bilayer
    • L.D.Jasenosky, G.Neumann, I.Lukashevich, et al. Ebola virus VP40-induced particle formation and association with the lipid bilayer. J Virol. 2001;75:5205–5214.
    • (2001) J Virol , vol.75 , pp. 5205-5214
    • Jasenosky, L.D.1    Neumann, G.2    Lukashevich, I.3
  • 34
    • 3142710288 scopus 로고    scopus 로고
    • Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles
    • J.M.Licata, R.F.Johnson, Z.Han, et al. Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J Virol. 2004;78:7344–7351.
    • (2004) J Virol , vol.78 , pp. 7344-7351
    • Licata, J.M.1    Johnson, R.F.2    Han, Z.3
  • 35
    • 80054771708 scopus 로고    scopus 로고
    • Advances in virus-like particle vaccines for filoviruses
    • K.L.Warfield, M.J.Aman. Advances in virus-like particle vaccines for filoviruses. J Infect Dis. 2011;204(Suppl 3):S1053–S1059.
    • (2011) J Infect Dis , vol.204 , pp. S1053-S1059
    • Warfield, K.L.1    Aman, M.J.2
  • 37
    • 84877031340 scopus 로고    scopus 로고
    • Human papillomavirus vaccines–immune responses
    • M.Stanley, L.A.Pinto, C.Trimble. Human papillomavirus vaccines–immune responses. Vaccine. 2012;30(Suppl 5):F83–F87.
    • (2012) Vaccine , vol.30 , pp. F83-F87
    • Stanley, M.1    Pinto, L.A.2    Trimble, C.3
  • 38
    • 40549138117 scopus 로고    scopus 로고
    • Current progress of DNA vaccine studies in humans
    • S.Lu, S.Wang, J.M.Grimes-Serrano. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines. 2008;7:175–191.
    • (2008) Expert Rev Vaccines , vol.7 , pp. 175-191
    • Lu, S.1    Wang, S.2    Grimes-Serrano, J.M.3
  • 39
    • 0032551189 scopus 로고    scopus 로고
    • DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge
    • L.Vanderzanden, M.Bray, D.Fuller, et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology. 1998;246:134–144.
    • (1998) Virology , vol.246 , pp. 134-144
    • Vanderzanden, L.1    Bray, M.2    Fuller, D.3
  • 40
    • 10744230259 scopus 로고    scopus 로고
    • Comparison of individual and combination DNA vaccines for B. Anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus
    • J.Riemenschneider, A.Garrison, J.Geisbert, et al. Comparison of individual and combination DNA vaccines for B. Anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine. 2003;21:4071–4080.
    • (2003) Vaccine , vol.21 , pp. 4071-4080
    • Riemenschneider, J.1    Garrison, A.2    Geisbert, J.3
  • 41
    • 0034575944 scopus 로고    scopus 로고
    • Adenovirus vectors for human gene therapy
    • M.M.Hitt, F.L.Graham. Adenovirus vectors for human gene therapy. Adv Virus Res. 2000;55:479–505.
    • (2000) Adv Virus Res , vol.55 , pp. 479-505
    • Hitt, M.M.1    Graham, F.L.2
  • 42
    • 84875525572 scopus 로고    scopus 로고
    • Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates
    • J.S.Richardson, S.Pillet, A.J.Bello, et al. Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J Virol. 2013;87:3668–3677.
    • (2013) J Virol , vol.87 , pp. 3668-3677
    • Richardson, J.S.1    Pillet, S.2    Bello, A.J.3
  • 43
    • 77954057355 scopus 로고    scopus 로고
    • Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus species
    • L.E.Hensley, S.Mulangu, C.Asiedu, et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus species. PLoS Pathog. 2010;6:e1000904.
    • (2010) PLoS Pathog , vol.6 , pp. e1000904
    • Hensley, L.E.1    Mulangu, S.2    Asiedu, C.3
  • 44
    • 73949160519 scopus 로고    scopus 로고
    • International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials
    • T.C.Mast, L.Kierstead, S.B.Gupta, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies:correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine. 2010;28:950–957.
    • (2010) Vaccine , vol.28 , pp. 950-957
    • Mast, T.C.1    Kierstead, L.2    Gupta, S.B.3
  • 45
    • 33644821543 scopus 로고    scopus 로고
    • Chimpanzee adenovirus vaccine protects against Zaire Ebola virus
    • G.P.Kobinger, H.Feldmann, Y.Zhi, et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology. 2006;346:394–401.
    • (2006) Virology , vol.346 , pp. 394-401
    • Kobinger, G.P.1    Feldmann, H.2    Zhi, Y.3
  • 46
    • 56149115867 scopus 로고    scopus 로고
    • Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice
    • M.A.Croyle, A.Patel, K.N.Tran, et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One. 2008;3:e3548.
    • (2008) PLoS One , vol.3 , pp. e3548
    • Croyle, M.A.1    Patel, A.2    Tran, K.N.3
  • 47
    • 80054737077 scopus 로고    scopus 로고
    • Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs
    • J.S.Richardson, M.C.Abou, K.N.Tran, et al. Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs. J Infect Dis. 2011;204(Suppl 3):S1032–S1042.
    • (2011) J Infect Dis , vol.204 , pp. S1032-S1042
    • Richardson, J.S.1    Abou, M.C.2    Tran, K.N.3
  • 48
    • 84855424528 scopus 로고    scopus 로고
    • A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs
    • J.H.Choi, S.C.Schafer, L.Zhang, et al. A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs. Mol Pharm. 2012;9:156–167.
    • (2012) Mol Pharm , vol.9 , pp. 156-167
    • Choi, J.H.1    Schafer, S.C.2    Zhang, L.3
  • 49
    • 79955387781 scopus 로고    scopus 로고
    • Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge
    • T.W.Geisbert, M.Bailey, L.Hensley, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol. 2011;85:4222–4233.
    • (2011) J Virol , vol.85 , pp. 4222-4233
    • Geisbert, T.W.1    Bailey, M.2    Hensley, L.3
  • 50
    • 33747369807 scopus 로고    scopus 로고
    • Generation of an adenoviral vaccine vector based on simian adenovirus 21
    • S.Roy, Y.Zhi, G.P.Kobinger, et al. Generation of an adenoviral vaccine vector based on simian adenovirus 21. J Gen Virol. 2006;87:2477–2485.
    • (2006) J Gen Virol , vol.87 , pp. 2477-2485
    • Roy, S.1    Zhi, Y.2    Kobinger, G.P.3
  • 51
    • 39549107344 scopus 로고    scopus 로고
    • Generation of biologically contained Ebola viruses
    • P.Halfmann, J.H.Kim, H.Ebihara, et al. Generation of biologically contained Ebola viruses. Proc Natl Acad Sci U S A. 2008;105:1129–1133.
    • (2008) Proc Natl Acad Sci U S A , vol.105 , pp. 1129-1133
    • Halfmann, P.1    Kim, J.H.2    Ebihara, H.3
  • 52
    • 0033940077 scopus 로고    scopus 로고
    • Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy
    • A.P.Durbin, M.H.Skiadopoulos, J.M.McAuliffe, et al. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy. J Virol. 2000;74:6821–6831.
    • (2000) J Virol , vol.74 , pp. 6821-6831
    • Durbin, A.P.1    Skiadopoulos, M.H.2    McAuliffe, J.M.3
  • 53
    • 0038586407 scopus 로고    scopus 로고
    • A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants
    • R.A.Karron, R.B.Belshe, P.F.Wright, et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J. 2003;22:394–405.
    • (2003) Pediatr Infect Dis J , vol.22 , pp. 394-405
    • Karron, R.A.1    Belshe, R.B.2    Wright, P.F.3
  • 54
    • 34249946893 scopus 로고    scopus 로고
    • Successful topical respiratory tract immunization of primates against Ebola virus
    • A.Bukreyev, P.E.Rollin, M.K.Tate, et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol. 2007;81:6379–6388.
    • (2007) J Virol , vol.81 , pp. 6379-6388
    • Bukreyev, A.1    Rollin, P.E.2    Tate, M.K.3
  • 55
    • 77249161128 scopus 로고    scopus 로고
    • Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic
    • A.A.Bukreyev, J.M.Dinapoli, L.Yang, et al. Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic. Virology. 2010;399:290–298.
    • (2010) Virology , vol.399 , pp. 290-298
    • Bukreyev, A.A.1    Dinapoli, J.M.2    Yang, L.3
  • 56
    • 0037213927 scopus 로고    scopus 로고
    • Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic
    • J.P.McGettigan, R.J.Pomerantz, C.A.Siler, et al. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J Virol. 2003;77:237–244.
    • (2003) J Virol , vol.77 , pp. 237-244
    • McGettigan, J.P.1    Pomerantz, R.J.2    Siler, C.A.3
  • 57
    • 80055058700 scopus 로고    scopus 로고
    • Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses
    • J.E.Blaney, C.Wirblich, A.B.Papaneri, et al. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol. 2011;85:10605–10616.
    • (2011) J Virol , vol.85 , pp. 10605-10616
    • Blaney, J.E.1    Wirblich, C.2    Papaneri, A.B.3
  • 58
    • 84943247429 scopus 로고    scopus 로고
    • Preclinical development of inactivated rabies virus-based polyvalent vaccine against rabies and filoviruses
    • M.Willet, D.Kurup, A.Papaneri, et al. Preclinical development of inactivated rabies virus-based polyvalent vaccine against rabies and filoviruses. J Infect Dis. 2015;212(Suppl 2):S414–S424.
    • (2015) J Infect Dis , vol.212 , pp. S414-S424
    • Willet, M.1    Kurup, D.2    Papaneri, A.3
  • 59
    • 0032897970 scopus 로고    scopus 로고
    • Attenuated vesicular stomatitis viruses as vaccine vectors
    • A.Roberts, L.Buonocore, R.Price, et al. Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol. 1999;73:3723–3732.
    • (1999) J Virol , vol.73 , pp. 3723-3732
    • Roberts, A.1    Buonocore, L.2    Price, R.3
  • 60
    • 0034467097 scopus 로고    scopus 로고
    • Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1
    • N.F.Rose, A.Roberts, L.Buonocore, et al. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol. 2000;74:10903–10910.
    • (2000) J Virol , vol.74 , pp. 10903-10910
    • Rose, N.F.1    Roberts, A.2    Buonocore, L.3
  • 61
    • 17944369239 scopus 로고    scopus 로고
    • An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants
    • N.F.Rose, P.A.Marx, A.Luckay, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell. 2001;106:539–549.
    • (2001) Cell , vol.106 , pp. 539-549
    • Rose, N.F.1    Marx, P.A.2    Luckay, A.3
  • 62
    • 84870601170 scopus 로고    scopus 로고
    • Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of filovirus infections
    • 2157-2526-S1-004
    • A.Marzi, H.Feldmann, T.W.Geisbert, et al. Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of filovirus infections. J Bioterror Biodef. 2011;S1(4):pii:2157-2526-S1-004.
    • (2011) J Bioterror Biodef , vol.S1 , Issue.4
    • Marzi, A.1    Feldmann, H.2    Geisbert, T.W.3
  • 63
    • 84859181562 scopus 로고    scopus 로고
    • Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates
    • C.E.Mire, A.D.Miller, A.Carville, et al. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis. 2012;6:e1567.
    • (2012) PLoS Negl Trop Dis , vol.6 , pp. e1567
    • Mire, C.E.1    Miller, A.D.2    Carville, A.3
  • 64
    • 2342455182 scopus 로고    scopus 로고
    • Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses
    • M.Garbutt, R.Liebscher, V.Wahl-Jensen, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol. 2004;78:5458–5465.
    • (2004) J Virol , vol.78 , pp. 5458-5465
    • Garbutt, M.1    Liebscher, R.2    Wahl-Jensen, V.3
  • 65
    • 84929511906 scopus 로고    scopus 로고
    • A recombinant vesicular stomatitis virus Ebola vaccine – preliminary report
    • J.A.Regules, J.H.Beigel, K.M.Paolino, et al. A recombinant vesicular stomatitis virus Ebola vaccine – preliminary report. N Engl J Med. 2015. [Epub ahead of print].
    • (2015) N Engl J Med
    • Regules, J.A.1    Beigel, J.H.2    Paolino, K.M.3
  • 66
    • 84964969174 scopus 로고    scopus 로고
    • Phase 1 trials of rVSV Ebola vaccine in Africa and Europe – preliminary report
    • S.T.Agnandji, A.Huttner, M.E.Zinser, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe – preliminary report. N Engl J Med. 2015;374:1647–1660.
    • (2015) N Engl J Med , vol.374 , pp. 1647-1660
    • Agnandji, S.T.1    Huttner, A.2    Zinser, M.E.3
  • 67
    • 84940952795 scopus 로고    scopus 로고
    • Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial
    • A.M.Henao-Restrepo, I.M.Longini, M.Egger, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein:interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386:857–866.• First study demonstrating efficacy of the rVSV–ZEBOV vaccine in humans.
    • (2015) Lancet , vol.386 , pp. 857-866
    • Henao-Restrepo, A.M.1    Longini, I.M.2    Egger, M.3
  • 68
    • 84928792708 scopus 로고    scopus 로고
    • Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus
    • C.E.Mire, D.Matassov, J.B.Geisbert, et al. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature. 2015;520:688–691.
    • (2015) Nature , vol.520 , pp. 688-691
    • Mire, C.E.1    Matassov, D.2    Geisbert, J.B.3
  • 69
    • 56649099057 scopus 로고    scopus 로고
    • Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses
    • T.W.Geisbert, K.M.Daddario-Dicaprio, J.B.Geisbert, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine. 2008;26:6894–6900.
    • (2008) Vaccine , vol.26 , pp. 6894-6900
    • Geisbert, T.W.1    Daddario-Dicaprio, K.M.2    Geisbert, J.B.3
  • 70
    • 65849373288 scopus 로고    scopus 로고
    • Mucosal immunization of cynomolgus macaques with the VSVΔG/ZEBOVGP vaccine stimulates strong Ebola GP-specific immune responses
    • X.Qiu, L.Fernando, J.B.Alimonti, et al. Mucosal immunization of cynomolgus macaques with the VSVΔG/ZEBOVGP vaccine stimulates strong Ebola GP-specific immune responses. PLoS One. 2009;4:e5547.
    • (2009) PLoS One , vol.4 , pp. e5547
    • Qiu, X.1    Fernando, L.2    Alimonti, J.B.3
  • 71
    • 84873202509 scopus 로고    scopus 로고
    • Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates
    • A.Marzi, F.Engelmann, F.Feldmann, et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A. 2013;110:1893–1898.
    • (2013) Proc Natl Acad Sci U S A , vol.110 , pp. 1893-1898
    • Marzi, A.1    Engelmann, F.2    Feldmann, F.3
  • 72
    • 80054753979 scopus 로고    scopus 로고
    • Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy
    • A.Marzi, H.Ebihara, J.Callison, et al. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis. 2011;204(Suppl 3):S1066–S1074.
    • (2011) J Infect Dis , vol.204 , pp. S1066-S1074
    • Marzi, A.1    Ebihara, H.2    Callison, J.3
  • 73
    • 67650383786 scopus 로고    scopus 로고
    • Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus
    • T.W.Geisbert, J.B.Geisbert, A.Leung, et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol. 2009;83:7296–7304.
    • (2009) J Virol , vol.83 , pp. 7296-7304
    • Geisbert, T.W.1    Geisbert, J.B.2    Leung, A.3
  • 74
    • 84892698411 scopus 로고    scopus 로고
    • Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus
    • C.E.Mire, J.B.Geisbert, A.Marzi, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus. PLoS Negl Trop Dis. 2013;7:e2600.
    • (2013) PLoS Negl Trop Dis , vol.7 , pp. e2600
    • Mire, C.E.1    Geisbert, J.B.2    Marzi, A.3
  • 75
    • 57149112519 scopus 로고    scopus 로고
    • Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates
    • T.W.Geisbert, K.M.Daddario-Dicaprio, M.G.Lewis, et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008;4:e1000225.
    • (2008) PLoS Pathog , vol.4 , pp. e1000225
    • Geisbert, T.W.1    Daddario-Dicaprio, K.M.2    Lewis, M.G.3
  • 76
    • 84924943114 scopus 로고    scopus 로고
    • Safety of recombinant VSV-Ebola virus vaccine vector in pigs
    • E.De Wit, A.Marzi, T.Bushmaker, et al. Safety of recombinant VSV-Ebola virus vaccine vector in pigs. Emerg Infect Dis. 2015;21:702–704.
    • (2015) Emerg Infect Dis , vol.21 , pp. 702-704
    • De Wit, E.1    Marzi, A.2    Bushmaker, T.3
  • 77
    • 33846909686 scopus 로고    scopus 로고
    • A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial
    • J.E.Martin, N.J.Sullivan, M.E.Enama, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. 2006;13:1267–1277.
    • (2006) Clin Vaccine Immunol , vol.13 , pp. 1267-1277
    • Martin, J.E.1    Sullivan, N.J.2    Enama, M.E.3
  • 78
    • 84922473334 scopus 로고    scopus 로고
    • Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial
    • U.N.Sarwar, P.Costner, M.E.Enama, et al. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis. 2015;211:549–557.
    • (2015) J Infect Dis , vol.211 , pp. 549-557
    • Sarwar, U.N.1    Costner, P.2    Enama, M.E.3
  • 79
    • 84928423301 scopus 로고    scopus 로고
    • Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial
    • H.Kibuuka, N.M.Berkowitz, M.Millard, et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults:a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet. 2015;385:1545–1554.
    • (2015) Lancet , vol.385 , pp. 1545-1554
    • Kibuuka, H.1    Berkowitz, N.M.2    Millard, M.3
  • 80
    • 78649703575 scopus 로고    scopus 로고
    • A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults
    • J.E.Ledgerwood, P.Costner, N.Desai, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine. 2010;29:304–313.
    • (2010) Vaccine , vol.29 , pp. 304-313
    • Ledgerwood, J.E.1    Costner, P.2    Desai, N.3
  • 81
    • 84934286956 scopus 로고    scopus 로고
    • Safety and immunogenicity of a nocel recombinant adenovirus type 5 vector based Ebola vaccine in healthyadults in China: preliminary report of a phase 1, randomized, double-blind, placebo-controlled clinical trial
    • F.-C.Zhu, L.-H.Hou, J.-X.Li, et al. Safety and immunogenicity of a nocel recombinant adenovirus type 5 vector based Ebola vaccine in healthyadults in China:preliminary report of a phase 1, randomized, double-blind, placebo-controlled clinical trial. Lancet. 2015;385:2272–2279.
    • (2015) Lancet , vol.385 , pp. 2272-2279
    • Zhu, F.-C.1    Hou, L.-H.2    Li, J.-X.3
  • 82
    • 84983215000 scopus 로고    scopus 로고
    • Chimpanzee adenovirus vector Ebola vaccine – preliminary report
    • J.E.Ledgerwood, A.D.DeZure, D.A.Stanley, et al. Chimpanzee adenovirus vector Ebola vaccine – preliminary report. N Engl J Med. 2015;373:775–776.
    • (2015) N Engl J Med , vol.373 , pp. 775-776
    • Ledgerwood, J.E.1    DeZure, A.D.2    Stanley, D.A.3
  • 83
    • 84959245846 scopus 로고    scopus 로고
    • Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study
    • O.De Santis, R.Audran, E.Pothin, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults:a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2015;16:311–320.
    • (2015) Lancet Infect Dis , vol.16 , pp. 311-320
    • De Santis, O.1    Audran, R.2    Pothin, E.3
  • 84
    • 84959184825 scopus 로고    scopus 로고
    • Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial
    • M.D.Tapia, S.O.Sow, K.E.Lyke, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo:a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016;16:31–42.
    • (2016) Lancet Infect Dis , vol.16 , pp. 31-42
    • Tapia, M.D.1    Sow, S.O.2    Lyke, K.E.3
  • 85
    • 84942194673 scopus 로고    scopus 로고
    • The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial
    • A.Huttner, J.-A.Dayer, S.Yerly, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine:a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2015;15:1156–1166.
    • (2015) Lancet Infect Dis , vol.15 , pp. 1156-1166
    • Huttner, A.1    Dayer, J.-A.2    Yerly, S.3
  • 86
    • 84908457744 scopus 로고    scopus 로고
    • Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents
    • G.Wong, J.Audet, L.Fernando, et al. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine. 2014;32:5722–5729.
    • (2014) Vaccine , vol.32 , pp. 5722-5729
    • Wong, G.1    Audet, J.2    Fernando, L.3
  • 87
    • 84880310429 scopus 로고    scopus 로고
    • Vaccines for viral hemorrhagic fevers–progress and shortcomings
    • D.Falzarano, H.Feldmann. Vaccines for viral hemorrhagic fevers–progress and shortcomings. Curr Opin Virol. 2013;3:343–351.
    • (2013) Curr Opin Virol , vol.3 , pp. 343-351
    • Falzarano, D.1    Feldmann, H.2
  • 88
    • 84936940562 scopus 로고    scopus 로고
    • Experimental inoculation of Egyptian rousette bats (Rousettus aegyptiacus) with viruses of the Ebolavirus and Marburgvirus genera
    • M.E.B.Jones, A.J.Schuh, B.R.Amman, et al. Experimental inoculation of Egyptian rousette bats (Rousettus aegyptiacus) with viruses of the Ebolavirus and Marburgvirus genera. Viruses. 2015;7:3420–3442.
    • (2015) Viruses , vol.7 , pp. 3420-3442
    • Jones, M.E.B.1    Schuh, A.J.2    Amman, B.R.3
  • 89
    • 0036547563 scopus 로고    scopus 로고
    • Safety studies of the oral rabies vaccine SAD B19 in striped skunk (Mephitis mephitis)
    • A.Vos, E.Pommerening, L.Neubert, et al. Safety studies of the oral rabies vaccine SAD B19 in striped skunk (Mephitis mephitis). J Wildl Dis. 2002;38:428–431.
    • (2002) J Wildl Dis , vol.38 , pp. 428-431
    • Vos, A.1    Pommerening, E.2    Neubert, L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.